Acumen pharmaceuticals to report second quarter 2025 financial results on august 12, 2025

Newton, mass., aug. 05, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, today announced that the company will report second quarter 2025 financial results on tuesday, august 12, 2025. the company will host a conference call and live audio webcast at 8:00 a.m. et to provide a business and financial update.
ABOS Ratings Summary
ABOS Quant Ranking